A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Pyridorin in Subjects With Nephropathy Due to Type 2 Diabetes

Trial Profile

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Pyridorin in Subjects With Nephropathy Due to Type 2 Diabetes

Recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Mar 2015

At a glance

  • Drugs Pyridoxamine (Primary)
  • Indications Diabetic nephropathies; Renal failure
  • Focus Therapeutic Use
  • Acronyms PIONEER
  • Sponsors NephroGenex
  • Most Recent Events

    • 24 Mar 2015 Status changed from planning to recruiting, based on a NephroGenex media release.
    • 24 Mar 2015 According to a media release, NephroGenex received support from the EMA on the new endpoint and the study design for their ongoing phase III trial in diabetic nephropathy. The EMA indicated that the current phase III program could support a Marketing Authorization Application for full market approval in Europe.
    • 26 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top